Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Minerva Neurosciences (NERV) EBT (2016 - 2026)

Minerva Neurosciences filings provide 2 years of EBT readings, the most recent being -$21.4 million for Q4 2021.

  • On a quarterly basis, EBT fell 192.88% to -$21.4 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$45.3 million, a 2357.92% decrease, with the full-year FY2025 number at -$14.2 million, up 31.21% from a year prior.
  • EBT hit -$21.4 million in Q4 2021 for Minerva Neurosciences, down from -$7.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $29.5 million in Q2 2020 to a low of -$21.4 million in Q4 2021.